The benefits of decentralized clinical trials (DCT) begin with a higher success rate in clinical trial data collection. However, the benefits of DCT also extend to patients by simplifying their journey through their involvement in clinical trial phases. Also, increasing transparency of patient enrollment in DCT can lower costs and increase efficiencies. DCT have the added benefit of reducing site burden, which ultimately leads to better care for all patients. Reducing site burden also results in fewer roadblocks to proper implementation of clinical trial phases that use site resources.
By leveraging technology and a data-science driven approach to patient enrollment, sponsors of clinical research can overcome traditional clinical research challenges and accelerate their trial timelines.
Join this webinar with Martin Kilsgård, Head of Product, Trialbee, and Kimberly Tableman, Chief Clinical Development Officer, Castor. The two featured speakers will discuss best practices for patient enrollment in DCT.
Martin Kilsgård, Head of Product, Trialbee
Martin has worked within software development and digital transformation for almost 15 years. He has held various leadership positions within digital product management and has a proven track record as a key strategist, coach and innovator. Martin has broad experience from large global organizations as well as small start-ups. Before joining Trialbee, Martin worked within the life sciences industry, initially as Product Manager at the telehealth provider Docly and as a Senior Business Consultant at CGI (digitalizing government healthcare in Sweden). Martin holds a Master of Science in Electrical Engineering from Lund’s University (Sweden) and is a certified Product Owner (Scrum Alliance).Message Presenter
Kimberly Tableman, Chief Clinical Development Officer, Castor
Kimberly Tableman is Chief Clinical Development Officer (CCDO) at Castor. She has more than 23 years of experience in clinical development and technology. Over the past decade, she has focused on applying digital health technologies to reimagine the patient journey. She was most recently CEO at Medicine X, and co-founder at Rabble Health, where she led the development and beta launch of a patient engagement platform to serve oncology patients. Prior to Medicine X, Kimberly held senior roles at GlaxoSmithKline (GSK), including Head of Patient Engagement and Head of Digital Clinical Trials. She has also worked at Pfizer, and began her career in management consulting at Cap Gemini Ernst & Young.Message Presenter
Who Should Attend?
Senior professionals, including clinical data managers, clinical project managers and study managers, who are working in:
- Digital Therapeutics
- Clinical Operations
- Clinical Research
- Research and Development
- Scientific Affairs
What You Will Learn
- Leverage technology to expand access to clinical research
- Increase transparency of patient enrollment to lower costs and increase efficiencies
- Reduce site burden with real-time analytics to quickly move patients through the enrollment process
Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug and play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security and reusability of data for researchers worldwide. For more information, visit www.castoredc.com.